nafamostat has been researched along with Sclerosis, Systemic in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wild, G | 1 |
| Watkins, J | 1 |
| Ward, AM | 1 |
| Hughes, P | 1 |
| Hume, A | 1 |
| Rowell, NR | 1 |
1 other study available for nafamostat and Sclerosis, Systemic
| Article | Year |
|---|---|
Complement activation in systemic sclerosis.
Topics: Adult; Benzamidines; Complement Activation; Complement C1q; Complement C3; Complement C3a; Complemen | 1990 |